Status:

COMPLETED

Safety and Performance of Electrodes Implanted in the Left Ventricle

Lead Sponsor:

EBR Systems, Inc.

Conditions:

Heart Failure

Ventricular Dysfunction

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The study is intended to demonstrate the safe implant of small receiver-electrodes into the endocardial surface of the left ventricle and to demonstrate its utility in providing cardiac resynchronizat...

Detailed Description

Eligible patients will undergo an acoustic window assessment using transthoracic echocardiography. Patients with adequate acoustic windows will undergo implantation of the WiCS-LV system. Patients wi...

Eligibility Criteria

Inclusion

  • Patients with standard indications for CRT based upon the most recent ESC/EHRA guidelines AND meeting criteria for one of these two categories:
  • Patients with previously implanted pacemakers or ICD's and meeting standard indications for CRT but in whom standard CRT is not advisable due to known high risk - referred to as "upgrades". Justifications for not using standard CRT must be documented in a CRF.
  • Patients in whom coronary sinus lead implantation or attempted implantation for CRT has failed to provide demonstrable therapy benefit - referred to as "untreated"

Exclusion

  • Inability to comply with the study follow-up or other study requirements
  • History of chronic alcohol/drug abuse and currently using alcohol/drugs
  • Non-ambulatory (or unstable) NYHA class 4
  • Contraindication to heparin
  • Contraindication to both chronic anticoagulants and antiplatelet agents
  • Triple anticoagulation therapy (warfarin, clopidogrel, ASA, and other agents)
  • Thrombocytopenia (platelet count \<150,000)
  • Contraindication to iodinated contrast agents
  • Intracardiac thrombus by transesophageal echocardiography
  • Age less than 18 years or greater than 75
  • Attempted IPG implant within 3 days
  • Life expectancy of less than 12 months
  • Chronic hemodialysis
  • Stage 4 or 5 renal dysfunction defined as GFR \<30
  • Grade 4 mitral valve regurgitation
  • Myocardial infarction within one month
  • Major cardiac surgery within one month
  • History of a pericardial effusion in prior procedures
  • Female of childbearing potential, pregnant, or breastfeeding (a pregnancy test will be obtained where applicable)
  • Non-cardiac implanted electrical stimulation therapy devices

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2019

Estimated Enrollment :

39 Patients enrolled

Trial Details

Trial ID

NCT01905670

Start Date

July 1 2013

End Date

November 1 2019

Last Update

July 9 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Na Homolce Hospital

Prague, Czechia, 150 30

2

Aalborg University Hospital

Aalborg, Denmark, 9100